{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:50:56Z","timestamp":1791546656569,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.xphs.2025.103806","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T15:39:19Z","timestamp":1746286759000},"page":"103806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigation of the suitability of utilizing plasma concentration as a surrogate to understand lung exposure of inhaled drug in rats: Different delivery methods of fluticasone propionate"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4046-7223","authenticated-orcid":false,"given":"Po-Chang","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-0920","authenticated-orcid":false,"given":"Cornelia H.","family":"Rinderknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Nagapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Durk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.xphs.2025.103806_bib0001","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.mayocp.2021.03.016","article-title":"Why we should target small airways disease in our management of chronic obstructive pulmonary disease","volume":"96","author":"Usmani","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.xphs.2025.103806_bib0002","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/jps.21714","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the suitability of using Fluticasone propionate and an acute rat lung inflammation model to differentiate lung versus systemic efficacy","volume":"98","author":"Chiang","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103806_bib0003","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/17476348.2017.1360769","article-title":"Airway inflammation in chronic obstructive pulmonary disease (COPD): a true paradox","volume":"10","author":"Eapen","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.xphs.2025.103806_bib0004","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11671-008-9234-1","article-title":"Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery","volume":"4","author":"Chiang","year":"2009","journal-title":"Nanoscale Res Lett"},{"issue":"7","key":"10.1016\/j.xphs.2025.103806_bib0005","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global Initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.xphs.2025.103806_bib0006","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.rmed.2005.11.020","article-title":"Systemic side effects of inhaled corticosteroids in patients with asthma","volume":"100","author":"Dahl","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.xphs.2025.103806_bib0007","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archinte.159.9.941","article-title":"Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis","volume":"159","author":"Lipworth","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.xphs.2025.103806_bib0008","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41533-023-00347-6","article-title":"Rational use of inhaled corticosteroids for the treatment of COPD","volume":"33","author":"Quint","year":"2023","journal-title":"npj Prim Care Respir Med"},{"key":"10.1016\/j.xphs.2025.103806_bib0009","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1378\/chest.124.6.2329","volume":"124","author":"Leone","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.xphs.2025.103806_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0091270003260334","article-title":"Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic\/pharmacodynamic perspective","volume":"44","author":"Rohatagi","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2025.103806_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121457","article-title":"The future of dry powder inhaled therapy: promising or discouraging for systemic disorders?","author":"Ye","year":"2022","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2025.103806_bib0012","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1015839430269","article-title":"Pharmacokinetic\/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration","volume":"9","author":"Hochhaus","year":"1992","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2025.103806_bib0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/jamp.2010.0836","article-title":"The particle has landed\u2014Characterizing the fate of inhaled pharmaceuticals","volume":"23","author":"Patton","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.xphs.2025.103806_bib0014","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1742-7843.2006.pto_355.x","article-title":"Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids","volume":"98","author":"Edsb\u00e4cker","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.xphs.2025.103806_bib0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2023.01.083","article-title":"Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies","volume":"355","author":"Gaikwad","year":"2023","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.xphs.2025.103806_bib0016","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s11095-010-0128-4","article-title":"Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modeling of venturi effects for agglomerated systems","volume":"27","author":"Wong","year":"2010","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2025.103806_bib0017","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.addr.2011.05.009","article-title":"In silico models of aerosol delivery to the respiratory tract\u2014Development and applications","volume":"64","author":"Longest","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2025.103806_bib0018","article-title":"Report No. 125\u2014Deposition, retention, and dosimetry of inhaled radioactive substances","author":"Cuddihy","year":"1997","journal-title":"NCRP"},{"issue":"3","key":"10.1016\/j.xphs.2025.103806_bib0019","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bcp.12999","article-title":"Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation","volume":"82","author":"Borghardtm","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2025.103806_bib0020","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/acs.molpharmaceut.9b00289","article-title":"Pulmonary dissolution of poorly soluble compounds studied in an ex vivo rat lung model","volume":"16","author":"Eriksson","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2025.103806_bib0021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/psp4.12270","article-title":"Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators","volume":"7","author":"Hendrickx","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2025.103806_bib0022","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/psp4.12074","article-title":"Systems pharmacology approach for prediction of pulmonary and systemic pharmacokinetics and receptor occupancy of inhaled drugs","volume":"5","author":"Boger","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2025.103806_bib0023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/jamp.2016.1306","article-title":"Predicting exposure after oral inhalation of the selective glucocorticoid receptor modulator, AZD5423, based on dose, deposition pattern, and mechanistic modelling of pulmonary disposition","volume":"30","author":"B\u00e4ckman","year":"2017","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"2","key":"10.1016\/j.xphs.2025.103806_bib0024","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/jps.24575","article-title":"Development of a novel lung slice methodology for profiling of inhaled compounds","volume":"105","author":"B\u00e4ckstr\u00f6m","year":"2016","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2025.103806_bib0025","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bcp.12780","article-title":"Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach","volume":"81","author":"Borghardt","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2025.103806_bib0026","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1089\/jamp.2015.1253","article-title":"Preclinical experimental and mathematical approaches for assessing effective doses of inhaled drugs, using mometasone to support human dose predictions","volume":"29","author":"Caniga","year":"2016","journal-title":"J Aerosol Med Pulm Drug Deliv J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.xphs.2025.103806_bib0027","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003088-200039001-00002","article-title":"Bioavailability of orally administered micronised Fluticasone propionate propionate","volume":"39","author":"Falcoz","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2025.103806_bib0028","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.0306-5251.2001.01493.x","article-title":"Pharmacokinetics and systemic activity of fluticasone propionate via Diskus and pMDI, and of budesonide via Turbuhaler","volume":"52","author":"Thorsson","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2025.103806_bib0029","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2125.1996.36110.x","article-title":"Pharmacokinetics of intravenous Fluticasone propionate in healthy subjects","volume":"41","author":"Mackie","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2025.103806_bib0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1183\/09031936.94.07010069","article-title":"Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects","volume":"7","author":"Borgstr\u00f6m","year":"1994","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2025.103806_bib0031","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1742-1241.2007.01382.x","article-title":"The DiskusTM: a review of its position among dry powder inhaler devices","volume":"61","author":"Chrystyn","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.xphs.2025.103806_bib0032","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/thx.46.10.712","article-title":"Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique","volume":"46","author":"Newman","year":"1991","journal-title":"Thorax"},{"key":"10.1016\/j.xphs.2025.103806_bib0033","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/thx.48.5.506","article-title":"Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction","volume":"48","author":"Melchor","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.xphs.2025.103806_bib0034","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/thx.45.6.469","article-title":"Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution","volume":"45","author":"Zainudin","year":"1990","journal-title":"Thorax"},{"key":"10.1016\/j.xphs.2025.103806_bib0035","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1164\/ajrccm.153.5.8630614","article-title":"The inhalation device influences lung deposition and bronchodilating effect of terbutaline","volume":"153","author":"Borgstr\u00f6m","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.xphs.2025.103806_bib0036","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/thorax.56.3.186","article-title":"Comparison of the systemic effects of fluticasone propionate propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects","volume":"56","author":"Harrison","year":"2001","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.xphs.2025.103806_bib0037","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1208\/s12248-013-9519-x","article-title":"Incorporation of physiologically based pharmacokinetic modeling in the evaluation of solubility requirements for the salt selection process: a case study using Phenytoin","volume":"15","author":"Chiang","year":"2013","journal-title":"AAPS J"},{"issue":"11","key":"10.1016\/j.xphs.2025.103806_bib0038","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1021\/mp400088q","article-title":"Systemic concentrations can limit the oral absorption of poorly soluble drugs: an investigation of non-sink permeation using physiologically based pharmacokinetic modeling","volume":"10","author":"Chiang","year":"2013","journal-title":"Mole Pharm"},{"key":"10.1016\/j.xphs.2025.103806_bib0039","series-title":"Biopharmaceutics Modeling and Simulations","author":"Sugano","year":"2012"},{"key":"10.1016\/j.xphs.2025.103806_bib0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1208\/s12248-009-9098-z","article-title":"Mechanistic approaches to predicting oral drug absorption","volume":"11","author":"Huang","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2025.103806_bib0041","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/17425250902835506","article-title":"Introduction to computational oral absorption simulation","volume":"5","author":"Sugano","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.xphs.2025.103806_bib0042","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1023\/A:1015827908309","article-title":"Upper gastrointestinal (GI) pH in young, healthy men and women","volume":"7","author":"Dressman","year":"1990","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2025.103806_bib0043","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.xphs.2018.03.015","article-title":"Exploring a kinetic model approach in biopharmaceutics: estimating the fraction absorbed of orally administered drugs in humans","volume":"107","author":"Chiang","year":"2018","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2025.103806_bib0044","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jps.2600570602","article-title":"New method for calculating the intrinsic absorption rate of drugs","volume":"57","author":"Loo","year":"1968","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.103806_bib0045","series-title":"Pharmacokinetics","first-page":"138","author":"Gibaldi","year":"1975"},{"issue":"1","key":"10.1016\/j.xphs.2025.103806_bib0046","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF01066595","article-title":"Application of the loo-riegelman absorption method","volume":"3","author":"Wagner","year":"1975","journal-title":"J Pharmacokinet Biopharm"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925002631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925002631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:06:26Z","timestamp":1751616386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925002631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0022354925002631"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103806","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of the suitability of utilizing plasma concentration as a surrogate to understand lung exposure of inhaled drug in rats: Different delivery methods of fluticasone propionate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103806"}}